PARAMOUNT, 2012 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of LCZ696 versus valsartan in

        Z

NCT00887588    Lancet 2012;380:1387-95  



Studied treatment LCZ696 titrated to 200 mg twice daily for 36 weeks
Control treatment valsartan titrated to 160 mg twice daily,



Patients
Group sizes149 / 152



Blindness double-blind Inclusion period
Follow-up duration 12 weeks Centers
Lost to FU geographical localisation
Primary endpoint change in NT-proBNP Design

phase 2



EndpointX1N1X0N0TE95% CI CV death - 149 - 152 no data all cause death - 149 - 152 no data HF hospitalization - 149 - 152 no data DC CV + hospitalization for HF - 149 - 152 no data0,22,01,0

Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 2014;16:671-7     [PMID: 24692284]   link to pdf   add to Mendeley  

Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95     [PMID: 22932717]   link to pdf   add to Mendeley  

ClinicalTrial.gov record NCT00887588



Registering number NCT00887588 (see trial on clinicaltrials.gov)
Code Name